Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics develops AlloNK, an allogeneic natural killer cell therapy for autoimmune diseases including refractory rheumatoid arthritis, Sjögren disease, systemic sclerosis, and myositis.
8-KSep 11Latest SEC filing, period to Sep 8
Aug 6Latest story
August 2026